Publications by authors named "J Le Treut"

Claim this Profile
A
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial.
David R Spigel, Virginie Westeel, Ian C Anderson, Laurent Greillier, Florian Guisier, Jacques Le Treut

Lancet Respir Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resected -mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study).
Jean-Bernard Auliac, Pascal-Alexandre Thomas, Olivier Bylicki, Florian Guisier, Hubert Curcio, Jacques Le Treut

Ther Adv Med Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.
Lionel Falchero, Florian Guisier, Marie Darrason, Arnaud Boyer, Charles Dayen, Jacques Le Treut

Lung Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy.
Grégoire Justeau, Eric Huchot, Yannick Simonneau, Magali Roa, Jacques Le Treut

Lung Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study.
T Payen, J Trédaniel, L Moreau, S Larivé, J Le Treut

Respir Med Res· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis